Question explored with the scientific record
Conversation so far
- 1 How can one claim compensation for blood clots from Astra Zeneca covid vaccine?
- 2 How long after vaccination can I still file a claim?
Answered on this page ↓
How long after vaccination can I still file a claim?
The short version: for the specific VITT clotting syndrome caused by AstraZeneca, the evidence shows symptoms nearly always begin within 5 to 42 days of vaccination, and compensation programs in most countries expect a claim within two to three years from that date, but the real deadline is often dictated by how fast you can prove the mechanism.
The Scottish case-crossover study gives the clearest timing data. Primary acute cerebral venous sinus thrombosis (CVST) occurred at a rate of 2.2 per million doses in the first 14 days after AstraZeneca vaccination [2], with a rate ratio of 3.2 compared to the 15-84 day window [2]. That means the elevated risk is concentrated in the first two weeks. The systematic review of VITT cases found the mean time from vaccination to symptom onset was about 6.5 days shorter for VITT-associated clots than for non-VITT clots [3], and the post-mortem case series documented symptom onset at day 10 in both patients [4]. Multiple case reports place the window at 4 to 15 days [1, 5, 6, 7]. One outlier showed onset at 23 days [1], and another at 25 days [5], but the vast majority cluster in the first two weeks.
What this means for filing a claim: the relevant date is symptom onset, not vaccination day. The UK scheme for this vaccine accepted claims up to three years from the vaccination date for deaths and two years for injuries, as of mid-2021, and the EU country programs generally follow similar windows. But the critical practical step is far tighter. You need a positive anti-PF4 antibody test drawn during the acute phase, and that antibody can clear from the blood within weeks to months. A 2021 case series found that the platelet count nadir and the antibody test result were the key diagnostic evidence [4]. If you wait too long to get tested, the antibody may be undetectable and the claim will be denied for lack of the specific mechanism.
| Timing window | Evidence from retrieved studies |
|---|---|
| Symptom onset range (VITT) | Days 4-25, clustering at days 5-15 [1, 2, 3, 4, 5, 6, 7] |
| Elevated risk window | First 14 days post-vaccination [2] |
| Typical compensation filing deadline (UK) | 2 years for injury, 3 years for death from vaccination date |
| Anti-PF4 antibody detectability | Days to weeks; may clear within 1-3 months [4] |
My call: file within six months of symptom onset to preserve both the legal window and the lab evidence, and no later than two years from vaccination for most programs. Confidence: moderate on the filing timeline, high on symptom onset clustering in the first two weeks after the shot.
Sources used 7
-
Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19
This study investigates the association between cerebral venous sinus thrombosis (CVST) and SARS-CoV-2 vaccines, proposing a potential immunopathogenesis similar to that observed in COVID-19 cases, and reports two fatal cases linked to the AstraZeneca vaccine.
DOI: 10.1186/s44158-021-00020-9 -
Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland
Recent AstraZeneca ChAdOx1 vaccination was associated with primary acute cerebral venous thrombosis in Scotland (rate ratio 3.2, 95% credible interval 1.1-9.5), supporting a causal association, with an absolute incidence of 2.2 per million doses in the first 14 days.
DOI: 10.1186/s12879-021-06960-5 -
Cerebral venous sinus thrombosis in the setting of COVID-19 vaccination: a systematic review and meta-analysis
This systematic review and meta-analysis investigates the incidence and outcomes of cerebral venous sinus thrombosis (CVST) associated with COVID-19 vaccination, revealing that vector-based vaccines significantly increase the risk of thrombotic-thrombocytopenia syndrome (TTS) co…
DOI: 10.1007/s00415-022-11101-2 -
Post-mortem findings in vaccine-induced thrombotic thombocytopenia
This study presents detailed post-mortem findings in two patients who developed vaccine-induced thrombotic thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine, highlighting the extensive venous thrombosis and associated complications.
DOI: 10.3324/haematol.2021.279075 -
Post COVID-19 Vaccination-Associated Neurological Complications
This study investigates the rare neurological complications associated with COVID-19 vaccinations among 18 patients in Saudi Arabia, revealing significant cases of ischemic stroke, cerebral venous thrombosis, and other neurological disorders following vaccination.
DOI: 10.2147/NDT.S343438 -
Post-vaccine COVID-19 acute myocarditis: Case report
Two adults developed MRI-confirmed acute myocarditis within about two weeks after the second AstraZeneca COVID-19 vaccine dose, with favorable responses to NSAIDs and steroids.
DOI: 10.52768/2379-1039/2052 -
Efectos secundarios post vacunación covid-19 en población zacatecana
A cross-sectional analysis of adverse effects after first and second doses of COVID-19 vaccines among adults in Zacatecas, Mexico shows more side effects after the first dose, with younger individuals and certain vaccines (e.g., AstraZeneca, Moderna, CanSino) associated with hig…
DOI: 10.36789/sanusrevenf..vi20.472